The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

The agreement grants Jumpcode access to ERS' CRISPR/Cas9 patent portfolio, empowering the company to advance the sensitivity and efficiency of next-generation sequencing (NGS) and expand ...

ERS Genomics (ERS), which was established to provide broad access to the foundational CRISPR/Cas9 intellectual property developed by Prof. Emmanuelle Charpentier announced that the European Patent ...

The study, published in Nucleic Acids Research, introduces BLU-VIPR, a method that allows researchers to control the gene-editing tool CRISPR using light. This innovation could significantly ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...

Using gene editing with CRISPR-Cas9, the team has been able to study these proteins without altering ... Dec. 13, 2024 — Microorganisms produce a wide variety of natural products that can be ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a life science tools company ...